Background and objective: As there is a sharp increase in the incidence of lung cancer in women in recent years, it has brought broad concerns with its unique clinical and epidemiological characteristics and better prognosis. The aim of this study is to analyze the clinical data of women with advanced non-small cell lung cancer (NSCLC) retrospectively to explore the prognostic factors.
Methods: Clinical data of 541 female patients with advanced NSCLC were collected and followed up till death. The primary endpoint is overall survival (OS). SPSS 11.0 statistical analysis software was used for univariate and multivariate analysis.
Results: The mean age is 59 years (20 years-86 years), adenocarcinoma account for 80.2% (434/541). The median OS was 15 months (95%CI: 13.87-16.13), and 1, 2, 5-year survival rates were 58.8%, 23.7% and 3.20% respectively. Univariate analysis showed that clinical stage, ECOG score, weight loss, clinical symptoms, liver/bone/brain metastasis and received more than one chemotherapy regimen, good response to the first-line chemotherapy, EGFR-TKI targeted therapy and radiotherapy treatment were significantly correlated with the OS and survival rate (P < 0.05). Combined with multivariate analysis, weight loss before treatment, ECOG score, received EGFR-TKI targeted therapy and response to first-line chemotherapy were independent prognostic factor for survival (P < 0.05).
Conclusions: There is a higher percentage of adenocarcinoma in female NSCLC. Weight loss before treatment, ECOG score, EGFR-TKI targeted therapy and response to first-line chemotherapy may become independent prognostic factors for survival of female patients with advanced NSCLC.
背景与目的: 随着女性肺癌发病率的攀升，其独特的临床和流行病学特征及良好预后引起了学界的关注。本研究通过回顾性分析女性晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的临床资料，探讨其预后相关因素。
方法: 收集541例女性晚期NSCLC患者的临床资料，并随访至死亡。主要观察指标为总生存（overall survival, OS）。采用SPSS 11.0统计软件进行生存分析。
结果: 全组腺癌占80.2%（434/541），总体中位OS为15个月（95%CI: 13.87-16.13），1年、2年、5年生存率分别为58.8%、23.7%和3.20%。单因素分析显示，临床分期、ECOG评分、体重下降、临床症状、血行转移和一线治疗后化疗方案数>1、一线化疗有效、曾接受靶向治疗或放疗均与中位OS明显相关（P值均 < 0.05）。治疗前体重下降、ECOG评分、靶向治疗及一线化疗有效为生存的独立预后因素（P值均 < 0.05）。
结论: 女性晚期NSCLC患者的病理类型以腺癌为主，体重下降、ECOG评分、接受靶向治疗及一线化疗有效可能成为女性晚期NSCLC患者生存的独立预后指标。